TY - JOUR
T1 - Pathways for Diagnosis and Multimodal Management, Including Botulinum Neurotoxin Therapy, in Shoulder Conditions Following Acquired Central Nervous System Lesions
AU - Biering-Sørensen, Bo
AU - Cordero-García, Carlos
AU - Boulias, Chris
AU - Hoad, Damon
AU - Bensmail, Djamel
AU - Molteni, Franco
AU - Genêt, François
AU - Wissel, Jörg
AU - Jacinto, Jorge
AU - Marque, Philippe
AU - Berweck, Steffen
PY - 2025/7/31
Y1 - 2025/7/31
N2 - There is limited published guidance available to help less experienced practitioners assess and manage shoulder conditions, including spasticity, after acquired central nervous system (CNS) lesions. To address this gap, 11 spasticity and dystonia experts convened in a 2023 meeting to build on existing guidance, provide consensus on best treatment practice, and develop expert recommendations to guide the diagnosis and treatment of complications of shoulder conditions following CNS lesions. Presentations by each expert on diagnosis and management were followed by discussion; consensus on assessment and treatment practices was identified and recommendations developed. The expert panel recommended an assessment approach structured using the following components: patient history, including interpretation of reported symptoms; observation of postures and pain responses; clinical examination with targeted tests for specific signs; diagnostic tests; and assessment of upper limb impairment, activity limitations, and participation restrictions. This assessment process and the recommended measures recognize the importance of identifying shoulder involvement in upper limb spasticity as part of the diagnostic process in shoulder conditions following CNS lesions. These recommendations provide a practical approach to diagnosis and treatment for clinicians who are less experienced in evaluating and treating such conditions, simplifying otherwise complicated clinical scenarios.
AB - There is limited published guidance available to help less experienced practitioners assess and manage shoulder conditions, including spasticity, after acquired central nervous system (CNS) lesions. To address this gap, 11 spasticity and dystonia experts convened in a 2023 meeting to build on existing guidance, provide consensus on best treatment practice, and develop expert recommendations to guide the diagnosis and treatment of complications of shoulder conditions following CNS lesions. Presentations by each expert on diagnosis and management were followed by discussion; consensus on assessment and treatment practices was identified and recommendations developed. The expert panel recommended an assessment approach structured using the following components: patient history, including interpretation of reported symptoms; observation of postures and pain responses; clinical examination with targeted tests for specific signs; diagnostic tests; and assessment of upper limb impairment, activity limitations, and participation restrictions. This assessment process and the recommended measures recognize the importance of identifying shoulder involvement in upper limb spasticity as part of the diagnostic process in shoulder conditions following CNS lesions. These recommendations provide a practical approach to diagnosis and treatment for clinicians who are less experienced in evaluating and treating such conditions, simplifying otherwise complicated clinical scenarios.
KW - Humans
KW - Muscle Spasticity/drug therapy
KW - Botulinum Toxins/therapeutic use
KW - Dystonia/diagnosis
KW - Central Nervous System Diseases/complications
KW - Shoulder/physiopathology
KW - pain
KW - type A
KW - spasticity
KW - botulinum toxins
KW - shoulder
UR - http://www.scopus.com/inward/record.url?scp=105014432508&partnerID=8YFLogxK
U2 - 10.3390/toxins17080385
DO - 10.3390/toxins17080385
M3 - Review
C2 - 40864061
SN - 2072-6651
VL - 17
JO - Toxins
JF - Toxins
IS - 8
M1 - 385
ER -